TEVOGEN BIO HOLDINGS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.82 USD | 0.00% |
|
0.00% | -92.63% |
| 05-13 | Investors Eye Key Inflation Data in Days Ahead as US Futures Trend Modestly Higher Monday | MT |
| 05-13 | Top Premarket Gainers | MT |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 135M 10.6B |
|---|---|---|---|---|---|
| Net income 2022 | -22M -1.73B | Net income 2023 | -60M -4.71B | EV / Sales 2022 | - |
| Net Debt 2022 | 34.52M 2.71B | Net Debt 2023 | 94.37M 7.41B | EV / Sales 2023 | - |
| P/E ratio 2022 |
-11.8
x | P/E ratio 2023 |
-4.56
x | Employees | 19 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 4.35% |
More Fundamentals
* Assessed data
More news
More press releases
| Current month | -18.00% | ||
| 1 month | -3.53% | ||
| 3 months | -88.82% | ||
| 6 months | -92.54% | ||
| Current year | -92.63% |
1 week
0.75
0.86
1 month
0.751.48
Current year
0.7521.09
1 year
0.7521.09
3 years
0.7521.09
5 years
0.7521.09
10 years
0.7521.09
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/05/24 | 0.82 | 0.00% | 127,383 |
| 23/05/24 | 0.82 | +5.85% | 268,393 |
| 22/05/24 | 0.7747 | -9.92% | 256,589 |
| 21/05/24 | 0.86 | +10.26% | 1,567,623 |
| 20/05/24 | 0.78 | -4.88% | 287,128 |
Delayed Quote Nasdaq, May 24, 2024 at 09:00 pm
More quotes
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The Company is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.
| 1st Jan change | Capi. | |
|---|---|---|
| -92.63% | 135M | |
| +67.53% | 63.85B | |
| -0.77% | 41.83B | |
| +45.66% | 40.65B | |
| -10.72% | 27.12B | |
| +13.30% | 26.52B | |
| -22.79% | 18.69B | |
| +4.70% | 12.73B | |
| +24.10% | 12.11B | |
| +27.41% | 12.07B |
- Stock Market
- Equities
- TVGN Stock
